These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

351 related items for PubMed ID: 14977831

  • 1. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
    Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C, Provencio M, Isla D, Taron M, Diz P, Artal A, Spanish Lung Cancer Group.
    Clin Cancer Res; 2004 Feb 15; 10(4):1318-25. PubMed ID: 14977831
    [Abstract] [Full Text] [Related]

  • 2. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.
    Ceppi P, Volante M, Novello S, Rapa I, Danenberg KD, Danenberg PV, Cambieri A, Selvaggi G, Saviozzi S, Calogero R, Papotti M, Scagliotti GV.
    Ann Oncol; 2006 Dec 15; 17(12):1818-25. PubMed ID: 16980606
    [Abstract] [Full Text] [Related]

  • 3. mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines.
    Shimizu J, Horio Y, Osada H, Hida T, Hasegawa Y, Shimokata K, Takahashi T, Sekido Y, Yatabe Y.
    Respirology; 2008 Jun 15; 13(4):510-7. PubMed ID: 18494946
    [Abstract] [Full Text] [Related]

  • 4. RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.
    Zhang GB, Chen J, Wang LR, Li J, Li MW, Xu N, Wang Y, Shentu JZ.
    Cancer Chemother Pharmacol; 2012 May 15; 69(5):1277-87. PubMed ID: 22302408
    [Abstract] [Full Text] [Related]

  • 5. Influence of genetic markers on survival in non-small cell lung cancer.
    Rosell R, Taron M, Camps C, López-Vivanco G.
    Drugs Today (Barc); 2003 Oct 15; 39(10):775-86. PubMed ID: 14668933
    [Abstract] [Full Text] [Related]

  • 6. Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.
    Mazzoni F, Cecere FL, Meoni G, Giuliani C, Boni L, Camerini A, Lucchesi S, Martella F, Amoroso D, Lucherini E, Torricelli F, Di Costanzo F.
    Lung Cancer; 2013 Nov 15; 82(2):288-93. PubMed ID: 24045016
    [Abstract] [Full Text] [Related]

  • 7. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery.
    Rosell R, Felip E, Taron M, Majo J, Mendez P, Sanchez-Ronco M, Queralt C, Sanchez JJ, Maestre J.
    Clin Cancer Res; 2004 Jun 15; 10(12 Pt 2):4215s-4219s. PubMed ID: 15217961
    [Abstract] [Full Text] [Related]

  • 8. A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer.
    Heo SJ, Jung I, Lee CK, Kim JH, Lim SM, Moon YW, Shim HS, Jeong J, Kim JH, Kim HR, Cho BC.
    Cancer Chemother Pharmacol; 2016 Mar 15; 77(3):539-48. PubMed ID: 26811178
    [Abstract] [Full Text] [Related]

  • 9. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer.
    Reynolds C, Obasaju C, Schell MJ, Li X, Zheng Z, Boulware D, Caton JR, Demarco LC, O'Rourke MA, Shaw Wright G, Boehm KA, Asmar L, Bromund J, Peng G, Monberg MJ, Bepler G.
    J Clin Oncol; 2009 Dec 01; 27(34):5808-15. PubMed ID: 19884554
    [Abstract] [Full Text] [Related]

  • 10. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis.
    Simon GR, Schell MJ, Begum M, Kim J, Chiappori A, Haura E, Antonia S, Bepler G.
    Cancer; 2012 May 01; 118(9):2525-31. PubMed ID: 22028294
    [Abstract] [Full Text] [Related]

  • 11. ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer.
    Su C, Zhou S, Zhang L, Ren S, Xu J, Zhang J, Lv M, Zhang J, Zhou C.
    Med Oncol; 2011 Dec 01; 28(4):1411-7. PubMed ID: 20467918
    [Abstract] [Full Text] [Related]

  • 12. Pharmacogenomics and gemcitabine.
    Rosell R, Cobo M, Isla D, Camps C, Massuti B.
    Ann Oncol; 2006 May 01; 17 Suppl 5():v13-16. PubMed ID: 16807441
    [Abstract] [Full Text] [Related]

  • 13. [Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines].
    Liu XQ, Wang WX, Lin L, Song ST.
    Zhonghua Zhong Liu Za Zhi; 2010 Jan 01; 32(1):17-21. PubMed ID: 20211060
    [Abstract] [Full Text] [Related]

  • 14. First-line gemcitabine plus cisplatin in nonsmall cell lung cancer patients.
    Li Y, Wang LR, Chen J, Lou Y, Zhang GB.
    Dis Markers; 2014 Jan 01; 2014():960458. PubMed ID: 24591771
    [Abstract] [Full Text] [Related]

  • 15. Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial.
    Vilmar AC, Santoni-Rugiu E, Sorensen JB.
    Ann Oncol; 2013 Feb 01; 24(2):309-314. PubMed ID: 23038758
    [Abstract] [Full Text] [Related]

  • 16. [Relations between RRM1 protein expression levels and effects of gemcitabine and cisplatin chemotherapy in advanced non-small cell lung cancer patients].
    Gao Z, Han B, Shen J, Gu A, Zhong H.
    Zhongguo Fei Ai Za Zhi; 2011 Apr 01; 14(4):340-4. PubMed ID: 21496433
    [Abstract] [Full Text] [Related]

  • 17. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer.
    Rosell R, Scagliotti G, Danenberg KD, Lord RV, Bepler G, Novello S, Cooc J, Crinò L, Sánchez JJ, Taron M, Boni C, De Marinis F, Tonato M, Marangolo M, Gozzelino F, Di Costanzo F, Rinaldi M, Salonga D, Stephens C.
    Oncogene; 2003 Jun 05; 22(23):3548-53. PubMed ID: 12789263
    [Abstract] [Full Text] [Related]

  • 18. Expression of ERCC1, RRM1 and LRP in non-small cell lung cancers and their influence on chemotherapeutic efficacy of gemcitabine concomitant with nedaplatin.
    Qiu ZQ, Zhao K.
    Asian Pac J Cancer Prev; 2014 Jun 05; 15(17):7303-7. PubMed ID: 25227833
    [Abstract] [Full Text] [Related]

  • 19. Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy.
    Kim M, Ku JH, Kwak C, Kim HH, Lee E, Keam B, Kim TM, Heo DS, Lee SH, Moon KC.
    PLoS One; 2015 Jun 05; 10(7):e0133371. PubMed ID: 26200905
    [Abstract] [Full Text] [Related]

  • 20. Targeted therapy in combination with gemcitabine in non-small cell lung cancer.
    Rosell R, Crino L, Danenberg K, Scagliotti G, Bepler G, Taron M, Alberola V, Provencio M, Camps C, De Marinis F, Sanchez JJ, Peñas R.
    Semin Oncol; 2003 Aug 05; 30(4 Suppl 10):19-25. PubMed ID: 12917817
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.